X
Daiichi gets speedy FDA review for rare cancer drug
https://pharmaphorum.com/news/daiichi-speedy-fda-review-rare-cancer-drug/
rare cancer
NICE recommends Pfizer’s Xalkori in rare lung cancer
NICE has issued a Final Appraisal Determination that recommends the use of Pfizer’s Xalkori (crizotinib) in England under the Cancer Drugs Fund (CDF) for patients with ROS1-positive advanced non-small cell lung cancer (NSCLC).
Immunocore’s rare cancer treatment gains UK Promising Medicine designation
Immunocore has gained a Promising Innovative Medicines (PIM) designation in the UK for its candidate immunotherapy for patients with metastatic uveal melanoma, a rare tumour of the eye.
